impress showcas capabl set stage share
gain opportun acceler earn growth
guidanc goal beat expect rais price target
 reiter ow rate take investor day
highlight
financi target provid path high singl digit top-line growth
includ revenu compound-annual-growth-rate versu ms/con estim
ebitda versu ms/con estim
importantli guidanc impli acceler organ growth across segment
support combin global healthcar domain expertis curat
data asset data analyt capabl technolog infrastructur
datapoint world insight valid iqvia data-centr strategi
world repres fastest growth area doubl digit growth
expect empow iqvia human data scienc cloud
world technolog reson client includ top pharma
compani exampl showcas includ case studi top pharma
compani showcas valu reduc observ studi cost
acceler patient recruit time emerg biopharma
showcas increas label extens improv abil predict
advers event biotech studi increas precis use ai
technolog partnership salesforc iqvia unifi patient-centr cloud
platform empow trial autom workflow translat improv
precis trial design acceler site select optim site use
patient engag higher retent reduc manual clinic
monitor acceler time submiss manag highlight
central monitor mobil cra exampl improv product
significantli streamlin role cra autom workflow
allow focu high-valu clinic task
core-pow smart clinic trial potenti game changer
industri sinc launch core-pow solut
incorpor activ studi emerg custom account
total core-pow solut custom iqvia dedic offer
 distribut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
base consensu methodolog
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
launch februari reson custom earli datapoint
enrol trial showcas improv perform faster averag
recruit rate faster site identif timelin fewer non-
enrol site look ahead manag expect substanti
runway growth opportun area silico trial gene therapi
oncolog ai/ml autom trial plan virtual trial
updat model estim rais price target
model revenu million
growth vs prior estim million
growth consensu million
growth rais ep estim
growth vs prior estim
growth consensu
growth also chang bull case
valu bear case valu detail
exhibit
updat dcf base price target follow
mid-germ growth rais mid-term growth rate
repres mid compani guidanc
ebitda growth rais mid-term growth rate
repres lower end compani guidanc
discount period discount back mid-year vs year end
previou model
valuat methodolog risk
ow pt dcf-base price target assum wacc
termin growth rate risk achiev pt includ project cancel
strateg deal lead price pressur margin deterior im synergi fail
materi client servic disrupt result im merger
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report ricki
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
may benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur inc
within last month receiv compens invest bank servic amerisourcebergen corp inc quest
next month expect receiv intend seek compens invest bank servic allscript healthcar
diplomat pharmaci inc laboratori corp america hold mckesson corpor
within last month receiv compens product servic invest bank servic
within last month provid provid invest bank servic invest bank client relationship
follow compani inc amerisourcebergen corp inc cerner corpor charl river
laboratori health corp diplomat pharmaci inc laboratori corp america hold
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amerisourcebergen corp
employe director consult director health corp person research analyst member research
 co llc make market secur amerisourcebergen corp
inc cerner corpor health corp diplomat pharmaci inc laboratori corp america hold
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
